👋 Hey, let’s get into it. Biotech funding just opened the floodgates.

Instead of going the traditional VC route, George Church’s Rejuvenate Bio is going straight to anyone with $250 and a dream. The company just launched a crowdfunding campaign, giving everyday investors a shot at owning equity in a gene therapy startup targeting chronic disease and aging.

The pitch is ambitious. Rejuvenate is building one-time gene therapies designed to turn the body into a “living factory” that restores youthful function. In preclinical work, including studies in dogs, its approach has shown the potential to reverse disease and extend lifespan. Now the question is whether the crowd wants in.

🧬 Lilly Locks In $2.2B Bet With Bezos-Backed AI Gene Editor
Eli Lilly is doubling down on genetic medicine with a deal worth up to $2.2 billion with Profluent, a Bezos-backed AI protein design company. The partnership focuses on recombinase-based gene editing, with Profluent using massive protein datasets to design new tools from scratch. Lilly gets rights to push candidates into the clinic, while Profluent collects milestones and royalties if things hit. This is Lilly’s second recombinase deal this year, signaling real conviction in next-gen editing beyond CRISPR. When pharma starts stacking bets in the same niche, it usually means something’s coming.

💰 AbbVie Makes a $1.45B Play for KRAS Inhibitor
AbbVie is stepping into one of oncology’s hottest battlefields with a deal worth up to $1.45 billion tied to Kestrel Therapeutics’ KRAS inhibitor. The structure keeps things flexible, with AbbVie funding development now and holding an option to acquire later if the data delivers. Kestrel just dosed its first patient in a phase 1 trial targeting multiple KRAS mutations across solid tumors. AbbVie wants a seat at the KRAS table, just not the whole bill… for now.

🇮🇹 Chiesi Drops $1.9B on Rare Disease Momentum
Italy’s Chiesi Group is making its biggest move ever, acquiring KalVista for $1.9 billion to bulk up its rare disease portfolio. The centerpiece is Ekterly, an oral hereditary angioedema treatment that secured FDA approval last year after a rocky regulatory path. Chiesi is betting it can accelerate adoption and turn Ekterly into a meaningful revenue driver on the road to €6 billion by 2030. Rare disease continues to be one of pharma’s favorite hunting grounds, and this deal shows mid-sized players are still very much in the game.

💵 Teva Bets $700M on Tourette’s Breakthrough
Teva is acquiring Emalex Biosciences for $700 million upfront, with more tied to milestones, to secure ecopipam, a late-stage Tourette syndrome candidate. The drug showed statistically significant improvements in reducing tics in phase 3 trials and could hit the FDA submission stage later this year. Teva sees an opportunity to disrupt a market dominated by imperfect treatments with tough side effects. If approved, this could become a cornerstone asset in Teva’s neuroscience push and a rare win in a space that has seen limited innovation.

🤑 AstraZeneca Eyes $80B Future
Strong oncology and rare disease growth pushed Q1 sales to $15.3B, reinforcing confidence in its ambitious 2030 revenue target.

❌ FDA Wants To Pull Amgen Drug Approval
Regulators propose pulling Tavneos after alleging manipulated data and raising concerns about safety and liver toxicity risks.

✅ Incyte’s Vitiligo Data Clears Phase 3
Povorcitinib hit endpoints in two trials, though efficacy slightly trails AbbVie’s Rinvoq in head-to-head comparisons.

🔥 AbbVie Raises Outlook Again
Q1 revenue topped $15B, driven by immunology blockbusters, giving AbbVie more firepower for future dealmaking.

📉 Regeneron’s Eylea Streak Ends
Quarterly sales dipped below $1B for the first time in 8 years as competition and regulatory delays take a toll.

🏆 Pfizer Extends Blockbuster Protection
Patent settlements delay generics for tafamidis, protecting billions in rare disease revenue into the next decade.

💉 Shingrix Carries GSK’s Quarter
Record sales of the vaccine helped GSK beat expectations, powered by strong U.S. demand and a new delivery format. Guess the relentless shingles commercials they run paid off after all.

The FDA wants to stop waiting and start watching.

In a move that could reshape drug development, the agency is piloting real-time access to clinical trial data. Instead of waiting for full datasets at the end of studies, regulators will be able to monitor safety signals and efficacy endpoints as they happen. AstraZeneca and Amgen are already testing the model, streaming trial data directly to the FDA during ongoing studies.

The motivation is hard to ignore. It typically takes 10 to 12 years for a new drug to reach patients, and nearly half of clinical development time is spent on paperwork rather than actual research. By tapping into live data, the FDA hopes to cut that dead time and move promising therapies through the pipeline faster.

There’s also a bigger strategic angle. Faster trials could help the U.S. stay competitive globally as other countries invest heavily in speeding up drug development…we’re looking at you China. If regulators can make earlier decisions and reduce delays between phases, it could make the U.S. a more attractive place to run trials and launch new therapies.

Still, speed isn’t free. Moving too quickly raises concerns about acting on incomplete data and potentially approving therapies that don’t fully hold up. The FDA is positioning this as a pilot for a reason, testing how real-time insights can be used without compromising safety and efficacy.

If it works, clinical trials may start to look less like a series of checkpoints and more like a continuous data stream. And that could fundamentally change how fast new medicines reach the market.

That’s how much Eli Lilly has already spent on M&A this year. Six deals in, and they’ve blown past any annual total from the last decade. GLP-1 cash is clearly being recycled straight back into pipeline building, and they don’t look close to done. With how often they’re making deals, we could dedicate a weekly newsletter just to Lilly.

Here’s what biotech Redditors are talking about:

💼 Consulting Curiosity Takes Over
A biotech Redditor shared a rare win, landing a director-level role after two years post-layoff and crediting consulting work along the way. Instead of just celebrating, the comments quickly shifted to one question: how do you actually get into consulting? The consensus was clear. Independent consulting usually comes after years of industry experience and strong networks, not as a fallback for early-career scientists. For most, the path runs through established firms or deep connections, not a LinkedIn headline change.

🤝 Networking Means Showing Up, Not Sliding Into DMs
Another thread broke down the PhD-to-industry transition, and the advice was blunt. Stop cold messaging strangers on LinkedIn. Real networking happens in person, at conferences, seminars, and even casual lab collaborations. Scientists who stand out are the ones who help others, share knowledge, and stay visible in real-world settings. The takeaway was simple. If people know your work and remember you, opportunities tend to follow.

📢 Novartis Calls Out Europe
CEO Vas Narasimhan says Europe’s drug pricing system needs a “complete rethink” or risk falling behind in innovation.

🎟️ $180M Voucher Sale Fuels Rocket Pharma
Rocket sold a priority review voucher for $180M, extending its runway and backing its cardiovascular gene therapy pipeline.

🏗️ AstraZeneca’s $400M UK Expansion Returns
AstraZeneca restarts a $400M investment project expected to create 1,000 jobs after pausing over pricing disputes.

🧗 Altitude Lab Is Training the Next Wave of Biotech Founders
Altitude Lab, backed by AI-focused techbio Recursion, is focused on turning scientists into company builders. Since 2020, startups in the program have raised $185M, launched multiple clinical trials, and pushed platform-first innovation. The model blends hands-on mentorship, weekly operator access, and capital connections to reduce early-stage friction. As biotech shifts back toward bold science over incremental validation, Altitude is positioning itself as a launchpad for the next generation of founders.

📜 April 30, 1796 — America’s First Medical Patent
Samuel Lee Jr. received the first U.S. patent for a medicinal product, his “bilious pills,” which promised to cure everything from stomach pain to scurvy. Backed by his father’s reputation and a strong dose of early marketing, the pills spread across the East Coast. It was the birth of American pharma… and arguably the first example of “broad label indications.”

We’ve officially reached the point where you can invest in gene therapy like it’s a Kickstarter campaign. If you need us, we’ll be deciding whether to invest $250 in longevity… or just buy groceries. 😅

That’s all for today. See you Tuesday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead